uniQure (QURE) AI Stock Analysis

1,118 Followers

Top Page

uniQure

(NASDAQ:QURE)

45Neutral

uniQure's stock score reflects significant financial and operational challenges, with volatile revenue and persistent losses weighing heavily. While technical analysis shows some stability, valuation metrics highlight risks. Positive developments in the clinical pipeline and financial management provide some optimism, but the stock remains a high-risk investment.

Positive Factors

Financial Performance

QURE reported a net loss per share of ($0.82) vs. consensus of ($1.00), indicating better-than-expected financial performance.

Regulatory Developments

QURE is on track to report initial data from the Ph1/2a study in 2H25, showing ongoing progress in their clinical trials.

Regulatory Progress

AMT-130 in Huntington’s disease (HD) remains on track for a potential accelerated approval, with the FDA recently granting Breakthrough Therapy designation.

Negative Factors

Market Reaction

The recent sell-off of QURE shares is seen as overdone and driven by concerns surrounding the appointment of Dr. Vinay Prasad as head of the FDA’s Center for Biologics Evaluation and Research, as well as by investor disappointment with data from competitor HD program PTC518.

Share Price Volatility

Volatility for QURE shares has been observed over the past few months on regulatory developments.

uniQure (QURE) vs. S&P 500 (SPY)

Market Cap

$692.57M

Dividend YieldN/A

Average Volume (3M)2.33M

Price to Earnings (P/E)―

Beta (1Y)1.80

Revenue Growth6.30%

EPS Growth29.17%

CountryUS

Employees209

SectorHealthcare

Sector Strength38

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.82

Shares Outstanding54,748,497

10 Day Avg. Volume2,874,356

30 Day Avg. Volume2,333,490

Financial Highlights & Ratios

PEG Ratio-6.28

Price to Book (P/B)-89.85

Price to Sales (P/S)0.00

P/FCF Ratio-3.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$36.86

Price Target Upside169.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

uniQure Business Overview & Revenue Model

Company DescriptionuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes MoneyuniQure generates revenue primarily through strategic collaborations, licensing agreements, and the development and commercialization of its proprietary gene therapy products. Key revenue streams include milestone payments and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve the co-development and commercialization of gene therapies, providing uniQure with financial support and access to broader markets. Additionally, uniQure seeks to commercialize its own therapies, aiming to receive direct sales revenue upon product approval and market launch. The company's earnings are significantly influenced by its ability to successfully advance its product pipeline through clinical trials and regulatory approvals, as well as its capacity to secure and maintain strategic alliances.

uniQure Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Shows how much revenue each business unit or product line generates, highlighting areas of strength and potential growth within the company’s portfolio.

Chart InsightsuniQure's revenue from the License segment has shown a gradual recovery since 2023, indicating potential stabilization after previous volatility. Contract Manufacturing revenue peaked in early 2024 but has since dropped to zero, suggesting a strategic shift or completion of key contracts. Collaboration revenue surged in early 2024, driven by new partnerships or projects, but has since declined, highlighting potential variability in this segment. The absence of earnings call commentary leaves these trends open to interpretation, but the shifts suggest strategic realignments or market-driven changes impacting revenue streams.

Data provided by:

Main Street Data

uniQure Financial Statement Overview

Summary

uniQure faces considerable financial challenges across all verticals. The income statement shows declining revenue and persistent losses, the balance sheet indicates financial distress with negative equity, and cash flow statements highlight liquidity issues. The company's financial health appears precarious, with significant risks that need addressing.

Income Statement

Negative

The income statement reveals substantial volatility in revenue with significant fluctuations over the years. The company experienced a revenue peak in 2021 but faced a sharp decline afterward. Net profit margins have been consistently negative, with a significant net loss in recent periods. The gross profit margin has seen a decline, indicating increased operational challenges. Overall, the company is struggling with profitability and stability.

Balance Sheet

Negative

The balance sheet shows high financial risk with negative stockholders' equity in the latest period, indicating insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total liabilities relative to assets emphasize leverage risk. The equity ratio is negative, reflecting financial instability. Overall, the balance sheet suggests significant financial distress.

Cash Flow

Negative

Cash flow analysis indicates negative free cash flow, with recent deterioration in operating cash flow. Despite a large influx from investing activities, it is not sufficient to cover the negative free cash flow, highlighting potential liquidity issues. The ratios related to net income cannot be calculated due to persistent net losses. Overall, cash flow management appears weak with ongoing challenges in generating positive cash flow.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
27.12M	15.84M	106.48M	524.00M	37.51M
	Gross Profit
25.85M	2.21M	103.14M	499.03M	-84.89M
	EBIT
-184.29M	-282.87M	-143.16M	310.62M	-125.43M
	EBITDA
-160.75M	-253.10M	-108.02M	319.00M	-126.97M
	Net Income Common Stockholders
-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
367.52M	617.89M	352.84M	556.26M	244.93M
	Total Assets
556.54M	831.69M	704.96M	809.18M	340.39M
	Total Debt
66.06M	138.41M	142.89M	135.72M	71.54M
	Net Debt
-92.87M	-102.95M	-85.12M	-420.53M	-173.39M
	Total Liabilities
563.29M	624.02M	228.96M	213.40M	96.49M
	Stockholders Equity
-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow		Free Cash Flow
-186.10M	-153.08M	-162.75M	270.52M	-144.31M
	Operating Cash Flow
-182.73M	-145.93M	-145.06M	287.96M	-134.83M
	Investing Cash Flow
162.97M	-205.69M	-182.73M	-67.39M	-9.48M
	Financing Cash Flow
-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

Technical Analysis Sentiment

Positive

Last Price13.70

Price Trends

50DMA

12.40

Positive

100DMA

13.60

Negative

200DMA

10.23

Positive

Market Momentum

MACD

0.19

Positive

RSI

52.44

Neutral

STOCH

46.40

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 13.7 is above the 20-day moving average (MA) of 13.51, above the 50-day MA of 12.40, and above the 200-day MA of 10.23, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 46.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Risk Analysis

uniQure disclosed 65 risk factors in its most recent earnings report. uniQure reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

uniQure Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$758.78M	4.23	28.12%	―	910.33%	―
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
DAWN	50 Neutral	$627.43M	―	-17.80%	―	―	56.10%
NTLA	50 Neutral	$816.24M	―	-57.92%	―	-13.37%	2.57%
QURE	45 Neutral	$692.57M	―	-241.16%	―	6.30%	29.17%
SYRE	43 Neutral	$893.23M	2.31	-50.47%	―	-100.00%	94.68%
RCKT	40 Underperform	$652.35M	―	-60.45%	―	―	6.99%

* Healthcare Sector Average

Performance Comparison

QURE

uniQure

13.70

8.69

173.45%

RCKT

Rocket Pharmaceuticals

6.50

-16.12

-71.26%

SYRE

Spyre Therapeutics

14.54

-23.26

-61.53%

NTLA

Intellia Therapeutics

8.50

-17.72

-67.58%

CVAC

CureVac

3.72

0.23

6.59%

DAWN

Day One Biopharmaceuticals

6.25

-9.92

-61.35%

uniQure Earnings Call Summary

Earnings Call Date:May 09, 2025

(Q1-2025)

% Change Since: 11.84%|

Next Earnings Date:Jul 31, 2025

Earnings Call Sentiment Neutral

The earnings call presented a balanced view with significant progress in regulatory and clinical advancements, particularly with AMT-130, and a strong financial position. However, the declines in revenue and immunosuppression-related adverse events were noted as challenges.

Q1-2025 Updates

Positive Updates

AMT-130 Regulatory Progress

AMT-130 received breakthrough therapy designation from the FDA in April and is on track for a planned BLA submission. The company has had multiple productive interactions with the FDA, focusing on preparing for this submission.

Pipeline Expansion

uniQure expanded its clinical pipeline with the initiation of three additional clinical studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS.

Strong Financial Position

uniQure has more than $400 million in cash as of March 31, 2025, providing financial flexibility to advance its pipeline, including the planned BLA submission and launch of AMT-130.

Reduced Expenses

Research and development expenses decreased to $36.1 million from $40.7 million year-over-year, and selling, general, and administrative expenses decreased to $10.9 million from $13.9 million in the same period in 2024.

Negative Updates

Revenue Decline

Revenue for Q1 2025 was $1.6 million compared to $8.5 million in the same period in 2024, due to a decrease in collaboration and contract manufacturing revenues.

Immunosuppression-Related Adverse Events

In Cohort 3, three serious adverse events related to immunosuppression were observed, including mania, MRSA infection, and fever, although all were resolved with standard care.

Company Guidance

During the uniQure First Quarter 2025 Earnings Conference Call, CEO Matt Kapusta highlighted several key metrics and guidance for the year. The company is advancing its gene therapy pipeline with four clinical stage programs, notably AMT-130 for Huntington's disease, which is on track for a BLA submission. The FDA granted AMT-130 breakthrough therapy designation, and productive interactions with the FDA have occurred, with a detailed regulatory update expected later this quarter. In terms of financials, uniQure holds over $400 million in cash as of March 31, 2025, after a $80 million follow-on offering, providing the financial flexibility to support ongoing programs. The company reduced its cash burn rate through strategic divestitures and restructuring, and its operations are funded into the second half of 2027. Additionally, the Phase 1/2 trials for refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS are progressing, with initial data from Fabry expected in the second half of 2025.

uniQure Corporate Events

Executive/Board Changes

uniQure Amends CEO Employment Agreement

Neutral

Apr 16, 2025

On April 15, 2025, uniQure, Inc., a subsidiary of uniQure N.V., entered into an Amended and Restated Employment Agreement with its CEO, Matthew Kapusta. The agreement outlines Mr. Kapusta’s compensation, including a base salary of $676,700, potential bonuses, and long-term incentives, as well as severance benefits in case of termination without cause or for good reason. These benefits vary depending on whether the termination occurs around a change in control of the company, with provisions for salary continuation, bonus payments, and accelerated vesting of equity awards.

Spark’s Take on QURE Stock

According to Spark, TipRanks’ AI Analyst, QURE is a Underperform.

uniQure’s stock score reflects significant financial challenges, with weak income, balance sheet concerns, and negative cash flow. The technical indicators signal ongoing negative momentum, and the valuation is unattractive due to persistent losses. The overall outlook is cautious, with financial instability being the primary concern.

To see Spark’s full report on QURE stock, click here.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.